Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F7 | P08709 | 9/20 | 0.82 |
| ▸ | F10 | P00742 | 5/20 | 0.82 |
| ▸ | F2 | P00734 | 4/20 | 0.55 |
| ▸ | MTOR | P42345 | 1/20 | 0.49 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
| ▸ | C1S | P09871 | 1/20 | 0.45 |
| ▸ | HPN | P05981 | 1/20 | 0.45 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.45 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.45 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.45 |
| ▸ | HGFAC | Q04756 | 1/20 | 0.45 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL236558 | 0.90 | F7 (1.00) | F7F10F2MTOR | |
| Hydrochloric Acid SCHEMBL234684 | 0.89 | F7 (0.98) | F7F10F2MTOR | |
| SCHEMBL13855065 | 0.83 | F10 (0.58) | F7F10F2PARP1C1S | |
| SCHEMBL13993085 | 0.83 | F7 (0.72) | F7F10F2MTORNPC1 | |
| SCHEMBL4961414 | 0.80 | F7 (0.67) | F7F10F2MTORNPC1 | |
| SCHEMBL4420144 | 0.77 | F7 (1.00) | F7F10F2ROCK2 | |
| Hydrochloric Acid SCHEMBL6365169 | 0.75 | ITGB3 (0.60) | F7F10F2PRSS1PRSS2 | |
| Amicarbalide SCHEMBL1818799 | 0.74 | PLAU (0.65) | F10F2HPNPRSS1PRSS2 | |
| SCHEMBL13855059 | 0.73 | F7 (0.70) | F7F10F2MTORNPC1 | |
| SCHEMBL10320867 | 0.73 | F10 (0.57) | F7F10MTORTSHRNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090130085-A1 | Amidino-Compounds for Stabilizing Factor VII Polypeptide Formulations | NOVO NORDISH HEALTHCARE AG (CH) | 2009-05-21 | — | — | US | disclosed |
| US-20090130085-A1 | Amidino-Compounds for Stabilizing Factor VII Polypeptide Formulations | NOVO NORDISH HEALTHCARE AG (CH) | 2009-05-21 | — | — | US | disclosed |
| US-20090130085-A1 | Amidino-Compounds for Stabilizing Factor VII Polypeptide Formulations | NOVO NORDISH HEALTHCARE AG (CH) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090130085-A1 | Amidino-Compounds for Stabilizing Factor VII Polypeptide Formulations | F7, F5, F8 | F7 1/4885F10 15/4885F2 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.